Source: BioSig Technologies, Inc.
BioSig Technologies, Inc. (OTCQB: BSGM),
a medical device company developing a proprietary platform designed to
address an unmet technology need for the $4.6 billion electrophysiology
(EP) marketplace, today announced that the Company has hired Sherpa
Technology Group as its Intellectual Property Advisor.
Sherpa
Technology Group (STG), formerly known as 3LP Advisors, is a leading
Silicon Valley IP advisory firm that assists clients at the intersection
of business, technology, and intellectual property. Established in 2008
by a small group of IP strategy veterans, STG has been providing
intellectual property and technology strategy support, including
partnership analysis, IP portfolio development, licensing, and
monetization strategy support to a number of high profile Silicon Valley
firms.
“We are very pleased to guide BioSig through their IP
strategy at this important time in the Company’s development, and we
look forward to exploring the opportunities for wider applications of
BioSig’s technology,” commented Kevin Rivette(1), Managing Partner of
Sherpa Technology Group, former Vice President at IBM Corporation, and
former Senior Advisor to The Boston Consulting Group.
“Over the
past six months we engaged with BioSig’s Board and management, as well
as independently interacted with some of the Company’s strategic
partners. We are very optimistic about BioSig’s future as a technology
company with cutting-edge signal processing hardware and software,”
added Andrew Filler(2), Partner and General Counsel of Sherpa Technology
Group.
“As BioSig advances toward commercialization, we needed a
world-class partner to build a solid IP strategy that will allow us to
apply our technology to the new field of bioelectronic medicine. The
impact that Kevin and the rest of the STG team(3) had on the IP
strategies for some of the most well-known tech companies in the world
was unmatched. Their ability to marry IP strategy with the establishment
of sustainable and profitable business models was an ideal fit with our
thinking and needs. Forging a long-term strategic relationship with STG
will cement our intellectual property portfolio as a leader in the
field,” said Kenneth Londoner, Chairman & Chief Executive Officer of
BioSig Technologies, Inc.
(1) Kevin Rivette is the former
Chairman of the USPTO oversight committee. In 2008, Kevin was named to
the IP Hall of Fame by IAM magazine. In 2009 he was named one of “The
World’s Leading IP Strategists”.
(2) Andrew Filler was named as one
of the top two corporate IP attorneys in Silicon Valley by the San
Jose/Silicon Valley Business Journal in 2011.
(3) Other key members
include: Ralph Eckardt, Managing Partner, was named as one of “The
World’s Leading IP Strategists” by IAM magazine; Peter Detkin, Senior
Advisor, was named as the second most influential “IP market maker” in
the world by IAM.
About Sherpa Technology Group
Founded
in 2008 as 3LP Advisors, Sherpa Technology Group is a strategy and
M&A advisor on technology and intellectual property ("IP") matters.
The firm's clients range from Fortune 500 companies, to emerging
technology companies, to investors and investment banks.
Sherpa
Technology Group has world-class experience in IP strategy, management
consulting, investment banking, and engineering. Members of its
leadership team formerly ran The Boston Consulting Group's IP Strategy
Practice and were responsible for authoring prominent books on IP
strategy, including Rembrandts in the Attic (2000) and The Invisible Edge (2009).
Sherpa Technology Group's team comprises IP pioneers who managed and
monetized leading patent estates for the world's most recognizable
companies, such as IBM Corporation, Intel Corporation, and Intellectual
Ventures. The firm has offices in Silicon Valley and Boston.
About BioSig Technologies
BioSig
Technologies is a medical device company developing a proprietary
technology platform designed to improve the $4.6 billion
electrophysiology (EP) marketplace (www.biosigtech.com).
Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to
commercialize its PURE EP(TM) System. The technology has been developed
to address an unmet need in a large and growing market.
The
PURE EP System is a novel cardiac signal acquisition and display system,
which is engineered to assist electrophysiologists in clinical decision
making during procedures to diagnose and treat patients with abnormal
heart rates and rhythms. BioSig’s main goal is to deliver technology to
improve upon catheter ablation treatments for the prevalent and deadly
arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and is working
toward FDA 510(k) clearance for the PURE EP System.
No comments:
Post a Comment